Pasithea Therapeutics (KTTA) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed TScan Therapeutics (TCRX) over the past year, losing 40.8% versus a loss of 89.0%. Over five years, TCRX leads with a -96.5% price change compared with -99.2% for KTTA. TScan Therapeutics is the larger company by market cap ($16.1 million vs $15.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | TCRX |
|---|---|---|
| Share price | $0.4675 | $0.238 |
| Market cap | $15.62M | $16.13M |
| 1-day change | +6.03% | +4.29% |
| YTD return | -63.76% | -76.20% |
| 1-year return | -40.82% | -89.03% |
| 5-year return | -99.22% | -96.47% |
| EPS (TTM) | $-1.67 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.06 | $2.57 |
| 52-week low | $0.281 | $0.224 |
| Distance from 52-week high | -77.31% | -90.74% |
| Analyst consensus | none | hold |
| Avg. price target upside | +541.71% | +320.17% |
| Average volume | 226.32K | 784.00K |
| Shares outstanding | 33.41M | 63.50M |
| Employees | 5 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed TCRX by 48.2 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
KTTA vs TCRX FAQ
Which is bigger, Pasithea Therapeutics or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $16.13M compared with $15.62M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, KTTA or TCRX?
KTTA returned -40.82% over the past 12 months, compared with -89.03% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and TScan Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Pasithea Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for TScan Therapeutics.